Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Unichem	ZONISAMIDE	zonisamide	CAPSULE;ORAL	214492-002	Jan 26, 2021	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Glenmark Pharms	ZONISAMIDE	zonisamide	CAPSULE;ORAL	077651-003	Jan 30, 2006	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Unichem	ZONISAMIDE	zonisamide	CAPSULE;ORAL	214492-003	Jan 26, 2021	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: April 24, 2026

Carbonic anhydrase inhibitors (CAIs) are a mature small-molecule class with established use in glaucoma and other ocular indications, plus well-defined systemic roles in altitude sickness, edema syndromes, epilepsy, and off-label pain conditions. The market is shaped by (1) a small set of differentiated compounds for ophthalmology, (2) long-cycle patent estates that extend beyond the original active ingredient, and (3) steady generic pressure in older chemotypes. The patent landscape is dominated by (a) formulation and device claims for topical/oral delivery, (b) polymorph and salt form strategies, (c) new combinations in ocular hypotensive regimens and adjunct seizure control, and (d) second-generation chemotypes targeting ocular penetration and tolerability.

Which carbonic anhydrase inhibitor products actually drive the market?

Core commercial actives in CAIs (global)

The CAI market concentrates around a limited set of internationally used actives:

Segment	Representative active ingredients	Notes on differentiation	Patent reality (typical)
Glaucoma (topical)	Dorzolamide, Brinzolamide	Topical CAIs are the most commercially durable due to chronic use and regimen integration	Original ingredient patents largely expired in major jurisdictions; estates live in formulations, polymorphs, and combinations
Glaucoma (systemic)	Acetazolamide	Longstanding, used as adjunct; older molecule with high generic penetration	Active ingredient patents expired; remaining value mostly in supply chains and limited formulation/device improvements
Adjunct seizures / altitude sickness / edema	Acetazolamide	Oral systemic use; broad historical use	Active ingredient genericized early; most new filings focus on combinations and improved tolerability
Emerging/limited geography	CAIs in combination regimens or new chemotypes	Differentiation is usually PK/PD, ocular penetration, and tolerability	Often newer and more patent-rich than older ophthalmics

Mechanistic anchor: CAIs inhibit carbonic anhydrase isoenzymes involved in aqueous humor generation (ocular) and in systemic acid-base regulation (systemic indications). This clinical mapping drives the patent targets: ocular delivery, sustained exposure, and combination regimens.

How the market behaves

Chronic ophthalmic demand
Glaucoma therapy is long-duration, which supports pricing power for differentiated brands even as generics enter. The bulk of revenue persistence comes from (a) switching friction (device and dosing familiarity), and (b) patent-protected formulations and fixed-dose combinations.
Generic speed in older chemotypes
Acetazolamide and many earliest CAI molecules face rapid generic substitution. Post-expiry value shifts to supply, product availability, and patient adherence programs rather than new therapeutic differentiation.
Regimen integration creates incremental IP
New CAIs or derivatives that reach the market often need to show added value in combination with prostaglandin analogs, beta-blockers, or alpha-agonists. This tends to generate patent families around “use with” combinations, dosing schedules, and fixed combination products.

What is the current patent landscape structure for CAIs?

Patent protection in CAIs typically clusters in four layers. For business planning, these layers map to where litigable claims usually sit:

1) Second medical uses (method-of-treatment)

Common claim types:

“A method of lowering intraocular pressure by administering CAI X”
“Use of CAI in combination with Y for glaucoma”
“Use in seizure disorders as adjunct therapy”
These claims often remain relevant even when active ingredient patents expire, but enforceability varies by jurisdiction, prosecution history, and clarity of the claimed regimen.

2) Formulation, salt/polymorph, and delivery systems

This is usually the most commercially meaningful layer for ophthalmology:

Topical ophthalmic formulations optimized for pH, viscosity, penetration enhancers, preservatives, and osmolarity
Salt form and polymorph selection where relevant to stability and bioavailability
Controlled-release or viscosity-modulating approaches to reduce dosing frequency

3) Combination products and fixed-dose combinations (FDC)

Claims around a defined ratio of CAI + another glaucoma drug
Claims around co-administration protocols with a defined timing window
Device-related claims when the product uses specialized containers or dosing systems

4) Combination-of-chemotype strategies (new CAI isoform targeting)

Newer R&D strategies aim at improved isoenzyme selectivity (e.g., CA-II vs other isoforms) for efficacy and tolerability. This can lead to:

New chemical entities (NCE) with fresh novelty
New crystalline forms for IP life extension
New dosing regimens tied to PK/PD findings

Where are the highest-value IP pockets: glaucoma or systemic?

Glaucoma: formulation and combination claims dominate

CAIs are embedded in topical glaucoma regimens with long patient duration. That drives:

High bar for tolerability and adherence (ocular irritation is a recurring theme)
Product differentiation via formulation engineering
IP families that focus on “how” the drug is delivered and “what else” it is paired with

Systemic: fewer commercial levers, more generic exposure

Acetazolamide is widely genericized. For systemic indications:

Patent life is harder to extend meaningfully without a new chemotype or a clinically differentiated combination
Claims often center on specific dosing schedules, adjunct use, or new indications with clearer regulatory or clinical differentiation

What does the key patent timeline imply for market entry and litigation risk?

CAIs are older in the public domain compared with many modern specialty oncology or biologics pipelines. For investors and strategists, the implication is not “no patent activity,” but “the business battle shifts to incremental IP.”

Practical entry sequencing

Active ingredient expiry is the first inflection
Once the core molecule patents fall away, market share moves quickly to generics unless the branded product has a still-protected formulation or combination.
Formulation and FDC claims are the second inflection
New entrants often launch “authorized generics” or label-compatible generics. Where the branded product has proprietary formulation or combination patents, disputes concentrate here.
Second medical use and regimen patents are the final inflection
These can be litigated, but enforceability depends on jurisdictional claim standards and evidence of inventive step/non-obviousness.

What patent families and legal anchors govern CAIs in major jurisdictions?

The legal mechanism: how CAI patents tend to be structured

Across jurisdictions, the typical structure for CAIs involves:

Basic patents covering the active ingredient (often long expired for older molecules)
Secondary patents for polymorphs/salts, formulations, and therapeutic methods
Regulatory data exclusivity and, where applicable, pediatric extensions that are not identical across regions

Reference points for glaucoma CAIs

Publicly documented CAI actives in ophthalmology include:

Dorzolamide and Brinzolamide as the principal topical CAIs used globally
Acetazolamide as a systemic adjunct

The patent landscape around these molecules is likely to be heavily concentrated in formulation and combination IP due to the maturity of active ingredient protection.

How should R&D teams prioritize targets within CAIs?

Patent-friendly differentiation targets

For new programs, the most patent-aligned differentiation options are:

Ocular formulation improvements
Reduce irritation, improve residence time, and increase ocular bioavailability without increasing toxicity.
Combination regimens with defined clinical rationale
Fixed combination products and defined dosing sequences can yield enforceable claims if supported by robust data.
New chemotypes or isoenzyme-selective inhibitors
Seek selectivity and exposure advantages to differentiate efficacy, tolerability, or dosing frequency.
Crystalline forms and stability packages
Polymorph and salt selection can be a robust extension path where the data package supports it.

What are the key competitive dynamics among CAI brands and generics?

Market shares are shaped by substitution constraints

Ocular tolerance affects switching rates, because patients and clinicians are sensitive to preservatives, pH, and viscosity.
Dosing schedule affects adherence. Once daily or fewer dosing may win, but only if clinically supported.
Combination convenience can dominate once FDCs are available.

Generics typically compete on cost and label equivalence

Where a branded product is protected by formulation or FDC patents, generic launch may be delayed or limited to strength and formulation variants that do not infringe.
Brand competition continues around patient retention and prescriber preference until secondary IP is exhausted or a design-around is cleared.

Which CAI patent strategies are most common for life-cycle extension?

1) Polymorph/salt and stability

New crystalline forms can provide patentable subject matter even when the molecule is known.
The business impact is real in ophthalmics where stability, shelf life, and uniformity matter.

2) Buffer/pH/vehicle and preservative systems

Preservative-free or alternative preservative strategies can support both market differentiation and IP.
Vehicle systems that control viscosity and release profile can be claim-protected.

3) Dosage regimens and combination protocols

Defined timing and dosing schedules can be claimed as methods of treatment.
Combination patents rely on clinical evidence that the regimen achieves a defined therapeutic outcome.

4) Device-linked claims (when present)

Certain ocular delivery systems can support additional claims around the container or dosing mechanism, though this is less common than formulation claims.

What does this mean for investors evaluating CAI companies?

Investment screening checklist

Use patent and product mapping to screen for non-obvious risk:

Is the company’s moat formulation-based or combination-based?
If yes, the main threat is a generic design-around rather than a full active ingredient competition.
Do patents cover the exact marketed strength, composition, and dosing?
If not, the patent may have limited practical enforcement value.
Is the remaining term meaningful in the lead markets?
Secondary patents can be enforceable late in the lifecycle, but they must still have term and defendable claim scope.

Expected competitive outcomes

Older actives: stable generic availability; limited patent-driven upside unless new formulations or combinations remain protected.
Newer programs: higher patent value but also higher clinical, regulatory, and trial execution risk. The patent moat must align with the product that actually reaches the market.

Key Takeaways

Q: 5) What patent strategy most often extends the commercial life of a CAI brand?

Life-cycle extension most often comes through formulation engineering and combination products rather than the mechanism or broad method claims alone.

Carbonic anhydrase inhibitors are a mature class with the market anchored by topical glaucoma use, where formulation and combination IP is the main differentiator.
Acetazolamide is highly genericized, so patent value is typically in incremental extensions rather than the core molecule.
Dorzolamide and brinzolamide drive much of the ophthalmic landscape; secondary estates tend to focus on vehicle/pH/preservative, polymorph/salt, and fixed-dose or method-of-treatment combinations.
For R&D and investment decisions, the enforceable moat usually sits in how the drug is delivered and how it is combined, not in the mechanism alone.

FAQs

1) What is the primary commercial indication for carbonic anhydrase inhibitors?

Glaucoma, especially as topical therapy, is the dominant chronic use case that shapes long-term demand and IP strategy.

2) Why do formulations matter so much for CAIs in ophthalmology?

Ocular tolerability and residence time depend on vehicle, pH, and preservative system, which are common claim targets for brand differentiation and for design-around barriers.

3) Are CAI active ingredient patents still the main competitive factor?

For older actives, core active ingredient patents are largely expired in major markets; competitive advantage typically shifts to secondary patents for formulations, salts/polymorphs, and combinations.

4) Do CAIs have meaningful patent opportunities in systemic indications?

They can, but systemic CAIs face stronger generic competition; value creation tends to require new combinations, specific regimens, or new chemotypes with clear clinical differentiation.

5) What patent strategy most often extends the commercial life of a CAI brand?

Life-cycle extension most often comes through formulation engineering and combination products rather than the mechanism or broad method claims alone.

References

[1] World Intellectual Property Organization. Patent Scope: Health and the Environment. WIPO. https://www.wipo.int/
[2] US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
[3] European Medicines Agency. EPAR and product information for ocular and systemic carbonic anhydrase inhibitors. EMA. https://www.ema.europa.eu/
[4] PubChem. Carbonic Anhydrase inhibitors: dorzolamide, brinzolamide, acetazolamide. National Library of Medicine. https://pubchem.ncbi.nlm.nih.gov/
[5] National Center for Biotechnology Information. Carbonic anhydrase inhibitor pharmacology and therapeutic uses. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/